Gufic Biosciences Limited stock analysis

Balancing Affordability with Innovation Challenge: India's emphasis on affordable and accessible medicines, including price-control mechanisms applicable to essential medicines, can place pressure on margins and influence investment decisions, particularly in segments requiring significant research, development and regulatory expenditure. 5 Economic Times – Pharma Exports FY26 | Economic Survey 2025–26 – External Sec

They will be seated in Mumbai, but of course, traveling 15 days of the month. So gradually, what we are trying is, as we have done it in Europe in the past by trying to get our own subsidiaries made in Ireland and U.K., where the marketing authorizations remain with us. In these markets also now actually not now, but since the last 2.5 years, we have been always saying that we are trying to get our registrations in.

RESEARCH, DEVELOPMENT AND THE PRODUCT ENGINE Research and development remains organised around three pillars: extending the Company's lyophilisation and aseptic capability, building a pipeline of differentiated complex injectables, and using selective in-licensing and partnership to reach beyond internal development capacity. Delivery platforms under development PLATFORM CLINICAL RATIONALE STATUS Dual-chamber Elimina

And hopefully, like I said, we should end up the year on around 40%, 45% capacity utilization. Margin expansion using the Indore facility would, of course, come once we have what we call our EU in place. EU market EU certification really opens a lot of markets for us.

Government initiatives such as the PLI schemes are further strengthening domestic manufacturing and investment. l Quality and Affordability: India's combination of internationally recognised manufacturing standards, extensive regulatory approvals and cost-efficient production has enabled its pharmaceutical companies to serve both regulated and emerging markets. The country's strong presence in the United States and E

Apart from that, we have taken validation batches. So in terms of pure capacity expansion, yes, the amount has gone from 18% to 22% last year 20% to 25% last year, then this year, close to 30%, 35%. And hopefully, like I said, we should end up the year on around 40%, 45% capacity utilization.

So we see a product mix of around like a liquid would be 20% in Indore, lyophilization would still be around 50%, 60%, but the remaining 20% would come 20%, 30% would come from the complex injectables also. So would it be fair to say that from a mix point of view, maybe midpoint of FY28, where we would be starting to see real operating leverage gains? Pranav Choksi: I hope before that because there are other things a

The audio call recordings and written transcript of such calls are submitted to the Stock Exchanges and are also uploaded on the Company's website at this link Thehttps://gufic.com/media/investors/updates/investormeeting. Company also hosts calls or meetings with institutional investors on request. l Investor Services corporaterelations@guficbio.comThe Company has a dedicated email address i.e.